[HTML][HTML] Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma
FL Locke, SS Neelapu, NL Bartlett, T Siddiqi… - Molecular Therapy, 2017 - cell.com
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the
multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28 …
multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28 …
Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 …
Background: Patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL) have
poor outcomes with currently available therapies, with a complete response (CR) rate of 8 …
poor outcomes with currently available therapies, with a complete response (CR) rate of 8 …
Phase II trial of co‐administration of CD19‐and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
W Sang, M Shi, J Yang, J Cao, L Xu, D Yan… - Cancer …, 2020 - Wiley Online Library
Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated
remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL) …
remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL) …
[HTML][HTML] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
SS Neelapu, FL Locke, NL Bartlett… - … England Journal of …, 2017 - Mass Medical Soc
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
[HTML][HTML] Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma
Abstract BACKGROUND: CTL019 (tisagenlecleucel) is an investigational chimeric antigen
receptor (CAR) T-cell therapy that identifies and eliminates CD19-expressing B cells …
receptor (CAR) T-cell therapy that identifies and eliminates CD19-expressing B cells …
[HTML][HTML] Overcoming barriers to referral for chimeric antigen receptor T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
MS Hoffmann, BD Hunter, PW Cobb, JC Varela… - … and Cellular Therapy, 2023 - Elsevier
Background Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-
Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, patients who …
Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, patients who …
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
VA Chow, M Shadman, AK Gopal - Blood, The Journal of the …, 2018 - ashpublications.org
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
BD Shah, MR Bishop, OO Oluwole… - Blood, The Journal …, 2021 - ashpublications.org
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …
[HTML][HTML] CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell …
Y Liang, H Liu, Z Lu, W Lei, C Zhang, P Li… - Journal of Hematology & …, 2021 - Springer
CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to
treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority …
treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority …